Ethylphenidate
Viewing r1 — May 11, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ethylphenidate (ethyl 2-phenyl-2-piperidin-2-ylacetate) — Gogaine, Burst — is a synthetic stimulant of the phenidate class. It is the ethyl ester homolog of methylphenidate, distinguished by stronger dopamine selectivity. Ethylphenidate is a dopamine–norepinephrine reuptake inhibitor, producing its effects by blocking presynaptic dopamine reuptake with approximately 13-fold greater potency than cocaine at the DAT.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methylphenidate, amphetamine, cocaine +1 moremethylphenidate, amphetamine, cocaine, dopaminergic stimulants show less
EPH was first identified as a metabolite formed when methylphenidate and ethanol are co-ingested.[2] It appeared on research chemical markets around 2011 as an unscheduled stimulant, triggering injection-related harm clusters in Scotland and incremental scheduling across multiple countries. The United States placed it in Schedule I of the Controlled Substances Act in November 2024.[3]
Subjective effects include stimulation, euphoria, focus enhancement, and a pronounced compulsive redosing urge. The experience is more recreational and less functionally enhancing than methylphenidate — a longer, less intensely euphoric stimulation where the drive to re-administer frequently exceeds the reward of subsequent doses.[4][5] Anxiety, paranoia, and cognitive fragmentation are common unsought effects at higher doses.
Dependence liability is moderate, supported by reward-pathway molecular changes in animal models;[6] nearly all documented fatalities involved polydrug combinations.[7][8] The compulsive redosing urge is the primary behavioral risk — escalating doses within a session compound cardiovascular strain and psychological destabilization. No clinical trials have been conducted; the current understanding rests on forensic case series, animal studies, and user reports.
History[edit]
Discovery
Ethylphenidate was not designed as a drug. Its existence was first recognized in 1999 when Markowitz et al. detected it in postmortem blood from individuals who had taken methylphenidate with alcohol.[2] The liver enzyme carboxylesterase 1 swaps methylphenidate's methyl ester for an ethyl group derived from ethanol, producing EPH as an in vivo metabolite. Patrick et al. formally synthesized and characterized all four stereoisomers in 2005, establishing EPH as a pharmacologically distinct compound with potent DAT blockade.[1]
Emergence as a novel psychoactive substance
EPH appeared on research chemical markets around 2011, sold as a legal stimulant alternative under names like "Gogaine" and "Burst." The EMCDDA formally notified it through the EU Early Warning System that year.[9] Between 2013 and 2015, EPH became widely injected in Scotland among existing heroin users,[8][10] contributing to a surge in harm-reduction service presentations and the largest HIV outbreak among people who inject drugs in the United Kingdom in three decades.[11]
Scheduling
Regulatory response proceeded incrementally: Austria controlled EPH in 2012, Germany in 2013, the United Kingdom via a Temporary Class Drug Order in 2015[12] followed by the blanket Psychoactive Substances Act in 2016, and Canada in 2017. The United States placed EPH in Schedule I effective November 2024.[3] Hospital presentations related to EPH declined significantly following the introduction of controls.[13]
The name "ethylphenidate" derives straightforwardly from its structure: an ethyl ester variant of methylphenidate. Street names "Gogaine" and "Burst" reflect its marketing as a cocaine substitute in the early research chemical era. EPH was also identified in UK prison supply chains, where paper impregnated with NPS including EPH was used to circumvent institutional drug controls.[14]
Chemistry[edit]
Structure
Ethylphenidate belongs to the phenidate (substituted piperidine) family. Its core structure consists of a piperidine ring bonded to a phenylacetate ester — the defining motif of the phenidate class. EPH differs from methylphenidate by a single substitution: an ethyl group replaces the methyl group at the carboxylate position. This one-carbon extension modifies transporter selectivity, shifting the compound toward stronger DAT preference relative to the NET.[1][5]
| Molecular formula | C₁₅H₂₁NO₂ |
| Molecular weight | 247.33 g/mol |
Stereochemistry
EPH has two chirality centers, producing four stereoisomers in two pairs: threo and erythro. Research chemical preparations consist of the racemic mixture threo mixture.[1] Only the d-threo (positive) enantiomer is pharmacologically active — the l-threo enantiomer is inactive at monoamine transporters.[15] This mirrors Methylphenidate, where only d-threo-methylphenidate produces meaningful dopamine reuptake inhibitor. Chiral separation in forensic contexts has been achieved using supercritical fluid chromatography.[16]
Physical properties
No peer-reviewed data on melting point, solubility, or thermal stability have been published. Ethylphenidate is typically encountered as a white crystalline powder or as its hydrochloride salt.
Pharmacology[edit]
Mechanism of action
Ethylphenidate blocks the DAT (DAT), preventing dopamine from being cleared from the synapse and elevating dopamine levels in reward, movement, and executive-function circuits.[6] It has weaker activity at the NET (NET) and negligible effect on serotonin reuptake.[1][5][17]
The active enantiomer, d-threo-ethylphenidate, blocks DAT approximately 13.6 times more potently than cocaine.[1] Unlike methylphenidate, which inhibits dopamine and norepinephrine reuptake with roughly equal strength, EPH is markedly more selective for dopamine.[15][5] This selectivity profile shapes both the subjective experience — more reward-focused, less arousing — and the risk profile, driving a stronger compulsive redosing urge.
Pharmacokinetics
No formal human pharmacokinetic studies of EPH as a standalone substance have been published. Key parameters — peak blood concentration, bioavailability, and half-life — remain uncharacterized in humans.
EPH is broken down primarily by carboxylesterase 1 (CES1), which cleaves the ethyl ester to yield ritalinic acid as the principal metabolite.[18] Minor pathways include hydroxylation and conjugation.[18] The ethyl ester may confer somewhat higher oral bioavailability than methylphenidate's methyl ester, as the bulkier group could reduce first-pass metabolism, though this remains unconfirmed.inferred
Neuroscience[edit]
Reward circuit activation
EPH's primary neural action is amplification of dopamine signaling in the brain's reward circuit. By blocking dopamine reuptake in the nucleus accumbens and related structures, EPH elevates dopamine in the pathway most directly involved in reward valuation, motivation, and reinforcement.[6]
Repeated EPH exposure in adolescent mice produced elevated ΔFosB — a molecular marker of addiction vulnerability — across the dorsal striatum, nucleus accumbens, and prefrontal cortex.[6] This transcription factor accumulates with chronic stimulant exposure and promotes compulsive drug-seeking by remodeling gene expression in reward regions.
Prefrontal function and the inverted-U
EPH's dopamine elevation in the prefrontal cortex likely drives the focus enhancement reported at lower doses.[4] Prefrontal dopamine follows an inverted-U dose-response for cognitive performance: moderate elevation enhances working memory and attention, while excessive dopamine produces the cognitive fragmentation and indecisiveness reported at higher doses.[4]
Repeated exposure impaired spatial learning in adolescent mice without corresponding changes in brain growth factor levels, suggesting EPH's cognitive effects operate through different pathways than some other stimulants.[6]
EPH's enhanced dopamine selectivity relative to methylphenidate raises the question of whether chronic use produces distinct long-term brain adaptations — different patterns of transporter regulation and circuit-level change. The absence of growth factor changes despite cognitive impairment in animal models[6] is unexplained. Robertson documented prolonged mental health effects persisting beyond cessation,[19] but their neurobiological basis remains uncharacterized.
Subjective Effects[edit]
The ethylphenidate experience centers on dopaminergic reward — a clean, focused stimulation at lower doses that sharpens attention and lifts mood, giving way to scattered, anxious cognition as the dose increases. The defining feature across all routes is a compulsive redosing urge disproportionate to the actual pleasure of subsequent doses, a pattern that distinguishes EPH from most stimulants in its class.[4] Set and setting modestly modulate the experience but do not override the pharmacological drive to re-administer.
Relative to cocaine, EPH produces a longer-lasting, less intensely euphoric stimulation with a stronger compulsive quality. Compared to methylphenidate, the character is more recreational and less functionally enhancing, reflecting EPH's greater dopamine selectivity and reduced noradrenergic contribution to executive arousal.[15][5]
Effect Grid
Clear stimulation with euphoria, pronounced focus enhancement, and thought acceleration. Motivation enhancement is apparent — tasks feel rewarding and purposeful. Communication flows readily, and sociability enhancement is well established. Time alteration may compress perceived duration.
Appetite suppression is strong. Cardiovascular effects become apparent: elevated heart rate and blood pressure are noticeable. Bruxism and jaw tension may emerge. Vasoconstriction produces noticeably cold hands and feet. Dehydration sensation and excessive sweating are common. Insomnia is expected for several hours after dosing.
The compulsive redosing urge emerges clearly at this tier and constitutes the primary behavioral risk. The drive to re-administer may exceed the subjective reward of subsequent doses.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity enhancement · Tinnitus · Auditory hallucinations · External hallucinations · Shadow people
Shadow people
Dry mouth · Heart rate perception changes · Insomnia · Pupil dilation · Body high · Excessive sweating · Muscle tension · Physical fatigue · Restlessness · Dehydration sensation · Bodily lightness · Headache · Nausea · Sexual arousal enhancement · Bruxism · Breathing alteration · Dizziness · Respiratory stimulation · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Motor control enhancement · Abnormal heartbeat · Constipation · Motor control impairment · Trembling · Tactile hallucination
Pupil dilation · Body high · Excessive sweating · Muscle tension · Physical fatigue · Restlessness · Dehydration sensation · Bodily lightness · Headache · Nausea · Sexual arousal enhancement · Bruxism · Breathing alteration · Dizziness · Respiratory stimulation · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Motor control enhancement · Constipation · Motor control impairment · Trembling · Tactile hallucination
Cognitive euphoria · Information processing enhancement · Analysis enhancement · Motivation enhancement · Immersion enhancement · Language enhancement · Memory enhancement · Thought organization · Aesthetic enhancement · Cognitive flexibility · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Creativity enhancement · Motivation suppression · Cognitive dysphoria · Cognitive impairment · Confusion · Thought disorganization · Thought loops · Thought deceleration
Immersion enhancement · Language enhancement · Memory enhancement · Thought organization · Aesthetic enhancement · Cognitive flexibility · Multiple thought streams · Novelty enhancement · Pattern recognition enhancement · Creativity enhancement · Motivation suppression · Cognitive dysphoria · Cognitive impairment · Confusion · Thought disorganization · Thought loops · Thought deceleration
Emotional enhancement · Anhedonia · Dysphoria · Emotional lability
Communication enhancement · Self-control enhancement · Sociability enhancement · Ego inflation · Depersonalization
Depersonalization
Timeline
Gradual awareness of mild stimulation — slight alertness increase and subtle mood shift. Effects remain sub-threshold for the first portion of this window.
Building stimulation with emerging focus enhancement and mood lift. Heart rate begins to rise and appetite suppression becomes noticeable.
Full stimulation, euphoria, and focus enhancement. Compulsive redosing urge is strongest during this phase. Cardiovascular effects (elevated heart rate, blood pressure) are most apparent.
Gradual decline in stimulation. Irritability, cognitive fatigue, and restlessness may emerge as dopaminergic stimulation fades. Appetite remains suppressed.
Residual wakefulness and appetite suppression persist. Depression, anhedonia, and physical fatigue are common. Cognitive fatigue may impair concentration.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- methylphenidate · amphetamine · cocaine
Toxicity
Acute toxicity
No lethal dose, lowest toxic dose, or therapeutic index has been established for ethylphenidate in any species. The exact human toxic dose is unknown.
Two postmortem case series provide the available reference data. Parks et al. reviewed 19 EPH-associated deaths in Scotland (2013–2014): postmortem blood concentrations ranged from 0.008 to over 2 mg/L, and EPH was named in the cause of death in five cases.[8] Maskell et al. reported seven fatalities in England (2013–2015), with blood concentrations from 0.026 to 2.18 mg/L; only one case involved EPH as the sole detected substance.[7]
Cardiovascular effects
Increased heart rate, elevated blood pressure, and raised body temperature are consistently reported — expected effects of dopamine and norepinephrine reuptake blockade.[4] Abnormal heartbeat appears in community reports. No controlled cardiovascular safety data exist.
Injection-related harms
Intravenous injection of EPH powder carries risks distinct from oral use, including serious blood vessel damage and tissue injury.[20] A surge in IV EPH use in Scotland from 2014 to 2015[10] was identified as a major factor in an HIV outbreak — the largest among people who inject drugs in the UK in 30 years.[11] EPH powder is not formulated for injection; this route carries risks of particulate blockage in blood vessels, abscess formation, and bloodborne virus transmission.
Psychological risks
Compulsive redosing is the dominant psychological risk. Soussan and Kjellgren identified compulsive redosing and binge patterns as the most prominent theme in their analysis of user reports — users described an overwhelming urge to re-administer that frequently overrode initial dose-limiting intentions.[4]
At higher doses, users report anxiety, paranoia, cognitive fragmentation, and indecisiveness.[4] Robertson documented prolonged psychiatric effects persisting beyond cessation of EPH use.[19] Animal data reinforce concern: ΔFosB elevation in reward-pathway regions following repeated exposure indicates long-term molecular changes associated with compulsive drug-seeking.[6]
Tolerance & dependence
No published human studies have characterized EPH tolerance or dependence.
Tolerance to euphoric and stimulatory effects is expected to develop with repeated use, based on class analogy with other dopamine reuptake blockers. Estimated tolerance half-life (~5 days) and full reset (~1.5 weeks) are structural-structural analog inferences, not EPH-specific measurements.inferred Cross-tolerance with other dopaminergic stimulants is expected.
Dependence liability is moderate. In mice, conditioned place preference at doses below the threshold for visible stimulation demonstrates reward value at low exposures, and ΔFosB elevation in reward regions marks molecular substrates of the transition from voluntary to compulsive use.[6] User self-reports corroborate moderate psychological dependence.[4] No formal withdrawal has been characterized, though post-cessation psychiatric effects have been reported.[19]
Drug interactions
Ethanol
The ethanol–EPH interaction is bidirectional and well-characterized. Co-ingestion of ethanol with methylphenidate produces EPH endogenously and increases methylphenidate blood levels by 40–100% through competitive enzyme inhibition.[21][22] When EPH is taken as a standalone substance, ethanol would be expected to inhibit its breakdown, potentially elevating blood concentrations and prolonging duration.[18] Combined stimulant–alcohol use carries additive cardiovascular risk.safety citation needed
Tramadol
Both EPH and tramadol lower the seizure threshold, creating additive seizure risk in combination. The combination is rated as potentially lethal. No published case report documents a specific EPH–tramadol fatality.[8][7]safety citation needed
MDMA
Combined use of EPH and MDMA produces additive cardiovascular stimulation — elevated heart rate, blood pressure, and body temperature — with potential for dangerous overheating. No published case report specific to this combination exists.safety citation needed
Polydrug mortality patterns
The majority of EPH-associated deaths involved co-administration with depressants — benzodiazepines (15/19 Scottish cases), opiates (11/19), and methadone (8/19).[8][7] Stimulant effects can mask depressant toxicity until cardiovascular collapse or respiratory failure occurs.
Contraindications
Heart conditions
EPH produces stimulant cardiovascular effects including increased heart rate, elevated blood pressure, and raised body temperature.[4] Pre-existing heart disease, uncontrolled high blood pressure, structural heart abnormalities, and irregular heartbeat history are absolute contraindications.inferred
MAOIs
Co-administration with monoamine oxidase inhibitors carries risk of dangerous blood pressure crisis through impaired catecholamine breakdown combined with reuptake blockade.inferred
Seizure disorders
EPH and several commonly co-used substances (tramadol, MDMA) lower the seizure threshold. Active seizure disorders or medications that reduce seizure threshold represent relative contraindications.inferred
Pregnancy
No reproductive toxicity data exist for EPH. By class analogy with methylphenidate, use during pregnancy is contraindicated.inferred
Harm Reduction[edit]
Forms & Identification
Ethylphenidate is most commonly encountered as a white crystalline powder or as its hydrochloride salt. Because EPH was sold through the research chemical market, purity and composition have varied significantly between batches and vendors. Reagent testing can help distinguish EPH from other stimulants but cannot confirm purity or rule out all adulterants — quantitative testing services provide the most reliable identification where available.
Guidelines
- Test the substance before use — reagent kits provide a first-line screen, but laboratory testing services offer definitive identification
- Pre-measure doses and separate remaining material before the session begins — do not keep bulk supply accessible
- Set a firm redosing limit before onset and communicate it to a trusted companion
- Stay hydrated but avoid overhydration — drink water steadily rather than in large volumes
- Eat a meal before use; stimulant appetite suppression makes post-onset eating unlikely
- Avoid injection — oral and insufflated routes carry substantially less risk than intravenous administration
Set & Setting
The compulsive redosing urge is EPH's defining risk factor and should shape every decision about context. Using alone increases the likelihood of unchecked redosing, while the presence of a sober companion or pre-set dose limits can interrupt the binge pattern. Avoid settings where remaining material is readily accessible in large quantities — physical separation from supply is one of the most effective interventions.
Aftercare & integration. The EPH comedown typically involves fatigue, low mood, irritability, and appetite rebound effect. Prioritize sleep — stimulant disruption of sleep architecture is cumulative, and recovery requires uninterrupted rest rather than sedative assistance where possible.
Eat nutrient-dense food as appetite returns. Avoid caffeine and other stimulants in the 24–48 hours following use. If a binge pattern occurred, expect the comedown to be proportionally more severe and longer-lasting. Persistent low mood, anxiety, or sleep disruption beyond 72 hours warrants consultation with a healthcare provider.
Recovery & Support
Repeated EPH use can develop into a pattern of compulsive bingeing that is difficult to interrupt without external support. The compulsive redosing urge distinguishes EPH from many stimulants — users frequently report that the drive to re-administer persists long after the subjective reward has diminished.
Support resources include SAMHSA's National Helpline (1-800-662-4357), local harm reduction services, and stimulant-specific peer support groups. Professional help is warranted when use has become difficult to control, when binges are increasing in frequency or duration, or when mental health symptoms persist between sessions.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, or body temperature hot enough to feel through clothing indicate a medical emergency. Severe confusion, paranoid ideation with self-harm risk, or inability to communicate also require immediate help.
Immediate steps:
- 1. Call emergency services
- 2. Place the person in the recovery position if unconscious but breathing
- 3. Keep them cool — remove excess clothing, apply cool water to forehead and neck
- 4. Do not restrain unless there is immediate danger of self-harm
- 5. Do not induce vomiting
What to tell the dispatcher: Name the substance (ethylphenidate or stimulant), estimated amount, time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Ethylphenidate was initially uncontrolled in most jurisdictions, allowing its sale as a "research chemical" or "legal high" through the early 2010s. Scheduling proceeded incrementally, driven by forensic identification in fatality cases and injection-related harm clusters. As of 2026, EPH is explicitly controlled in the United States, United Kingdom, Canada, Germany, and Austria, with additional jurisdictions applying structural analog provisions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | DEA final rule effective 21 November 2024[3] |
| United Kingdom | Banned (Psychoactive Substances Act 2016) | Temporary Class Drug Order from 10 April 2015;[12] extended June 2016;[23] subsequently covered by blanket PSA ban from 26 May 2016 |
| Germany | Anlage II BtMG (Schedule II) | Controlled under Narcotics Act since 17 July 2013 |
| Austria | Controlled (NPSG) | New Psychoactive Substances Act, effective 1 January 2012 |
| Canada | Schedule III (CDSA) | Added to Controlled Drugs and Substances Act on 5 May 2017 |
| Australia | Analogue control | Captured as methylphenidate analogue under existing legislationcitation needed |
| Sweden | Controlled | Referenced in ACMD documentation as controlled[12] |
| Denmark | Controlled | Referenced in ACMD documentation as controlled[12] |
Analogue considerations
In jurisdictions without specific EPH scheduling, analogue control provisions may apply. EPH is a direct structural analog of methylphenidate (a Schedule II substance in the United States), differing only in the ester substituent. Prior to its explicit Schedule I placement in November 2024, the US Federal Analogue Act could be invoked against EPH when intended for human consumption. In Australia, EPH is reportedly captured under state and federal analogue provisions, though specific scheduling instruments have not been independently verified.citation needed
references
- [1]
- [2] ^abMarkowitz JS, Logan BK, Diamond F, Patrick KS (1999) Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion. — Journal of Clinical Psychopharmacology PMID:10440465
- [3]
- [4]
- [5]
- [6]